Conavi Medical Corp. has filed a preliminary short form prospectus for an offering of common shares and pre-funded warrants in Canada. The company plans to use the net proceeds for obtaining FDA clearance for the next generation Novasight Hybrid system and for commercial launch in the U.S. The offering is expected to close on December 12, 2025, subject to regulatory approvals. Securities will also be offered through private placement outside of Canada. For more information, the preliminary prospectus is available on SEDAR+ at www.sedarplus.ca. This press release is not an offer to sell securities in the United States.

Read more at GlobeNewswire: Conavi Medical Corp. Announces Proposed Public Offering of